Xceleron and JCL Bioassay form early phase clinical trial partnership
Partnership hopes to expand access to analytical platforms for use in early drug development.
Accelerator MS (AMS) provider, Xceleron (MS, USA), has recently announced its partnership with LC–MS/MS proprietors, JCL Bioassay (IL, USA). The new venture will offer drug developers in North America, Europe and Asia access to design expertise and a range of highly sensitive analytical platforms for use in early clinical investigation.
In recent years, drug-development investigations in Phase 0 and enriched Phase I have been used to study a range of endpoints, including drug presence at the tissue or cells of interest, absolute bioavailability and human metabolism. Such investigations have led to reliable and cost-effective alternatives to current decision-making, leading Xceleron and JCL Bioassay into the development of over 100 analytical methods for investigations in these phases.
According to Michael Butler, Chief Executive Officer of Xceleron, “This partnership emphasizes the critical role of contemporary analytical platforms in driving down the cost of drug development. Whether in Phase 0 or enriched Phase I, we can confidently provide critical pharmacokinetic and pharmacodynamic information before Phase II.”
Both companies have recently invested in purpose-built laboratories for ultra-low level analyses under GLP and GCP conditions. Jenny Lin, Vice President of Operations and Chief Scientific Officer of JCL Bioassay, stated that, “With 27 years of experience in providing services for bioassay work coupled with-state-of-the-art analytical instruments, our researchers are well positioned to conduct ultrasensitive bioanalyses. This has led to the continuous growth of our company as a leader in the bioanalytical field and enables our customers to make rapid and precise decisions for their drug development programs”. Xceleron and JCL Bioassay anticipate their partnership will result in the geographical and technical scope of their services.
Source: Xceleron and JCL Bioassay announce partnership in early clinical investigations.
